| Literature DB >> 31775780 |
Claudia Casellato1,2, Emilia Ambrosini3, Andrea Galbiati4, Emilia Biffi5, Ambra Cesareo5, Elena Beretta5, Francesca Lunardini4, Giovanna Zorzi6, Terence D Sanger7,8, Alessandra Pedrocchi4.
Abstract
BACKGROUND: This study is aimed at better understanding the role of a wearable and silent ElectroMyoGraphy-based biofeedback on motor learning in children and adolescents with primary and secondary dystonia.Entities:
Keywords: Biofeedback; Dystonia; EMG; Learning; Sensory-motor deficits; Wearable devices
Mesh:
Year: 2019 PMID: 31775780 PMCID: PMC6882366 DOI: 10.1186/s12984-019-0620-y
Source DB: PubMed Journal: J Neuroeng Rehabil ISSN: 1743-0003 Impact factor: 4.262
Fig. 1Experimental set-up and raw data. a) a secondary dystonia subject performing the experiment at Scientific Institute E. Medea. b) a primary dystonia subject performing the experiment at Politecnico di Milano. c and d an example of recorded dataset: 10-movement sequence of the figure-8 task, performed by a healthy subject at 30 bpm: 3D kinematics (c) and EMG envelopes (d). Vertical dashed lines identify every figure-8 repetitions. Flexor Carpi Radialis (FCR), Extensor Carpi Radialis (ECR), Biceps Brachii (BIC), Triceps Brachii (TRIC), Anterior Deltoid (AD), Lateral Deltoid (LD), Posterior Deltoid (PD), and Supraspinatus (SS)
Fig. 2Biofeedback device. Picture and block scheme of the biofeedback device
Clinical and demographic details as well as training parameters of the patients recruited for the study
| Subject | Age [years] | Sex | Dystonia | Drugs / DBSa | Tested arm | BAD armb | Figure-8 size (circle radius [cm]) | Target Speeds [bpm]c | BF target muscle |
|---|---|---|---|---|---|---|---|---|---|
| P1 | 10 | F | I | Trihexyphenidyl | Right | 1 | 4 | 100; 80; 60 | AD |
| P2 | 10 | F | I | Trihexyphenidyl | Right | 1 | 4 | 80; 60; 50 | FCU |
| P3 | 16 | M | I | None | Right | 1 | 4 | 100; 80; 60 | AD |
| P4 | 17 | F | I | DBS | Right | 1 | 4 | 100; 80; 60 | FCU |
| P5 | 19 | M | I | Trihexyphenidyl | Right | 1 | 4 | 100; 80; 60 | ECR |
| P6 | 8 | M | I | Trihexyphenidyl | Right | 1 | 4 | 80; 60; 50 | FCU |
| P7 | 8 | M | I | L-Dopa/Carbidopa | Right | 1 | 4 | 100; 80; 60 | FCU |
| S1 | 14 | M | II | None | Right | 2 | 4 | 60; 50; 40 | LD |
| S2 | 10 | M | II | None | Right | 2 | 4 | 60; 50; 40 | ECR |
| S3 | 8 | M | II | None | Right | 1 | 4 | 20 | ECR |
| S4 | 16 | F | II | DBS | Right | 3 | 7 | uncontrolled | BIC |
| S5 | 13 | M | II | Trihexyphenidyl | Left | 3 | 4 | 40; 30; 20 | LD |
| S6 | 6 | F | II | None | Right | 1 | 4 | 80; 60; 40 | FCU |
| S7 | 8 | F | II | Trihexyphenidyl | Right | 1 | 7 | 30; 40 | AD |
a) DBS: Deep Brain Stimulation. b) BAD of the dominant/tested arm: 0 (absent) - 4 (severe). c) Among target speed, the speed used for training is highlighted in bold.
Fig. 3EMG signals along figure-8 trace. Example of EMG activations of one healthy subject for one target speed (30 bpm). They are mapped on the output task (figure-8 trace). In all the overlapped repetitions, each EMG profile envelope is normalized on the maximum in that repetition. Each empty circle is the mean value of the EMG normalized profile in small time windows whose width is calibrated to create a downsampling to match the kinematic sampling frequency (102 samples, to downsample from 2048 Hz to 20 Hz). One single repetition is shown in the inset for AD. The colormap ranges from blue (low muscle activation) to red (high muscle activation). The direction of the drawing and the consequent four quarters of the figure-8 are depicted
Fig. 4Example of outcome measures of the kinematic and muscular performance collected in four representative subjects. For each outcome measure, one example for one healthy subject, one primary dystonia (P4), one severe secondary dystonia (S5) and one mild secondary dystonia (S1) are reported, in green, in blue, in dark red and in light red, respectively. a) SATO, as normalized Error versus normalized Time. Each of the 30 points represents one repetition of figure-8. The linear regression is depicted as dashed lines. b) CV as function of the normalized time. Each of the 30 points represents one figure-8 repetition. The linear regression is depicted as dashed lines. c) Dissimilarity (0–1) of wrist, elbow, and shoulder trajectories (mean and standard among the 30 repetitions of each subject). d) TCI indices for the three principal muscles (BIC, AD, and PD). Each muscle is reported as a stacked bar of x and y components (mean values among the three series (3 × 10 repetitions) for each subject)
Results of the statistical analysis
| Healthy subjects | Patients Group | BF+ | BF- | P-value (Dystonia x Day x Block)b | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D1 | D5 | D1 | D5 | |||||||||
| Time*Error ↓ | 0.052 (0.009) | I | 0.068 (0.014) | 0.057 (0.009) | 0.061 (0.01) | 0.056 (0.004) | < 0.001 | 0.050 | 0.965 | 0.002 | 0.700 | 0.136 |
| II | 0.109 (0.067) | 0.107 (0.056) | 0.117 (0.071) | 0.114 (0.079) | 0.821 | 0.567 | ||||||
| CVspeed ↓ | 0.162 (0.023) | I | 0.258 (0.174) | 0.246 (0.1) | 0.244 (0.073) | 0.205 (0.061) | < 0.001 | 0.001 | 0.019 | < 0.001 | 0.061 | 0.258 |
| II | 0.675 (0.267) | 0.614 (0.285) | 0.74 (0.296) | 0.663 (0.227) | < 0.001 | 0.708 | ||||||
| DissEL ↓ | 0.358 (0.075) | I | 0.376 (0.104) | 0.372 (0.113) | 0.362 (0.095) | 0.362 (0.098) | 0.942 | 0.129 | 0.764 | 0.007 | 0.004 | 0.257 |
| II | 0.43 (0.092) | 0.391 (0.107) | 0.441 (0.186) | 0.422 (0.088) | 0.002 | 0.022 | ||||||
| DissSHO ↓ | 0.345 (0.068) | I | 0.424 (0.129) | 0.374 (0.113) | 0.397 (0.104) | 0.363 (0.037) | < 0.001 | 0.125 | 0.154 | < 0.001 | 0.004 | 0.209 |
| II | 0.552 (0.134) | 0.497 (0.198) | 0.574 (0.215) | 0.553 (0.152) | 0.040 | 0.023 | ||||||
| Repeatability (%) ↑ | 97.5 (1.2) | I | 93.3 (5.4) | 95.2 (1.6) | 95 (1.9) | 94.8 (3.6) | 0.080 | 0.521 | 0.005 | 0.050 | 0.710 | 0.310 |
| II | 84.8 (6.6) | 84.4 (9.7) | 79.7 (5.8) | 81 (8) | 0.253 | 0.465 | ||||||
| TCIBIC ↑ | 0.423 (0.109) | I | 0.40 (0.107) | 0.414 (0.209) | 0.444 (0.225) | 0.452 (0.113) | 0.502 | 0.877 | 0.098 | 0.414 | 0.175 | 0.124 |
| II | 0.254 (0.137) | 0.269 (0.082) | 0.343 (0.118) | 0.199 (0.118) | 0.135 | 0.078 | ||||||
| TCIAD ↑ | 0.66 (0.102) | I | 0.522 (0.104) | 0.558 (0.114) | 0.564 (0.099) | 0.583 (0.132) | 0.061 | 0.857 | 0.599 | 0.004 | 0.028 | 0.046 |
| II | 0.399 (0.188) | 0.542 (0.11) | 0.404 (0.172) | 0.325 (0.185) | 0.040 | 0.018 | ||||||
| TCIPD ↑ | 0.405 (0.15) | I | 0.397 (0.109) | 0.429 (0.125) | 0.422 (0.183) | 0.435 (0.094) | 0.103 | 0.928 | 0.193 | 0.579 | 0.291 | 0.242 |
| II | 0.287 (0.082) | 0.336 (0.081) | 0.337 (0.084) | 0.238 (0.108) | 0.558 | 0.168 | ||||||
a) Linear mixed-model considering separately primary and secondary dystonia subjects. b) Linear mixed-model considering the whole sample. In red, p < 0.05
Results of the effect size analysis
| Patients Group | Block | Time*Error | CVspeed | DissEL | DissSHO | Repeatability | TCIBIC | TCIAD | TCIPD |
|---|---|---|---|---|---|---|---|---|---|
| Primary | 0.915 | 0.084 | 0.045 | 0.407 | 0.463 | 0.074 | 0.326 | 0.272 | |
| 0.680 | 0.581 | −0.144 | 0.348 | 0.256 | 0.199 | 0.247 | 0.255 | ||
| Secondary | 0.042 | 0.221 | 0.390 | 0.324 | −0.049 | 0.130 | 0.929 | 0.605 | |
| 0.040 | 0.293 | −0.308 | 0.114 | 0.185 | −1.222 | −0.192 | −0.756 |
In orange, large effect size (> 0.8); in blue medium (0.5–0.8); in light grey small (0.2–0.5).
Fig. 5Comparison between dystonia patients and healthy subjects. For each outcome measure, a normality range was identified as the 95% confidential internal achieved by the group of healthy subjects. Mean values obtained by patients in each single session were compared to the normality range and used to represent a map: darker color indicates values within the normality range, lighter color indicates values outside the normality range. White cells indicate data not available due to acquisition failures and/or technical issues